View article

Objective:

Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced clinically meaningful weight loss in a phase 2 study in obese individuals without diabetes. The present randomized phase 3 trial assessed the efficacy of liraglutide in maintaining weight loss achieved with a low-calorie diet (LCD).

Methods:

Obese/overweight participants (⩾ 18 years, body mass index⩾ 30 kg m− 2 or⩾ 27 kg m− 2 with comorbidities) who lost⩾ 5% of initial weight during a LCD run-in were randomly assigned to liraglutide 3.0 mg per day or placebo (subcutaneous administration) for 56 weeks. Diet and exercise counseling were provided throughout the trial. Co-primary end points were percentage weight change from randomization, the proportion of participants that maintained the initial⩾ 5% weight loss, and the proportion that lost⩾ 5% of randomization weight (intention-to-treat analysis). ClinicalTrials. gov identifier …